These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 19787818)

  • 1. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up.
    Corey KE; Kane E; Munroe C; Barlow LL; Zheng H; Chung RT
    Hepatology; 2009 Oct; 50(4):1030-7. PubMed ID: 19787818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirin.
    Lange CM; von Wagner M; Bojunga J; Berg T; Farnik H; Hassler A; Sarrazin C; Herrmann E; Zeuzem S
    Eur J Gastroenterol Hepatol; 2010 Nov; 22(11):1303-7. PubMed ID: 20729742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lipid kinetics during dual antiviral therapy in patients with chronic hepatitis C].
    Jiménez Macías FM; Barrero Alor F; Casado Monge PG; Ramos Lora M; Pujol de la Llave E; Ruíz-Frutos C
    Med Clin (Barc); 2015 Jun; 144(12):536-43. PubMed ID: 24726260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations between serum lipids and hepatitis C antiviral treatment efficacy.
    Ramcharran D; Wahed AS; Conjeevaram HS; Evans RW; Wang T; Belle SH; Yee LJ;
    Hepatology; 2010 Sep; 52(3):854-63. PubMed ID: 20690192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct-acting antiviral agents against hepatitis C virus and lipid metabolism.
    Kanda T; Moriyama M
    World J Gastroenterol; 2017 Aug; 23(31):5645-5649. PubMed ID: 28883690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients.
    del Valle J; Mira JA; de los Santos I; López-Cortés LF; Merino D; Rivero A; Girón JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Pineda JA
    AIDS; 2008 May; 22(8):923-30. PubMed ID: 18453851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy.
    Harrison SA; Rossaro L; Hu KQ; Patel K; Tillmann H; Dhaliwal S; Torres DM; Koury K; Goteti VS; Noviello S; Brass CA; Albrecht JK; McHutchison JG; Sulkowski MS
    Hepatology; 2010 Sep; 52(3):864-74. PubMed ID: 20568303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotype specific peripheral lipid profile changes with hepatitis C therapy.
    Pedersen MR; Patel A; Backstedt D; Choi M; Seetharam AB
    World J Gastroenterol; 2016 Dec; 22(46):10226-10231. PubMed ID: 28028371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Hepatol; 2007 Mar; 46(3):403-10. PubMed ID: 17126448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensified peginterferon α-2a dosing increases sustained virologic response rates in heavy, high viral load hepatitis C genotype 1 patients with high low-density lipoprotein.
    Harrison SA; Abdurakhmanov D; Shiffman ML; Bakulin I; Mazur W; Rodriguez-Torres M; Silva GF; Cheinquer H; Messinger D; Connell EV; McKenna M; Tatsch F; Reddy KR;
    J Clin Gastroenterol; 2013 Mar; 47(3):271-9. PubMed ID: 22951527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study.
    Giordanino C; Bugianesi E; Smedile A; Ciancio A; Abate ML; Olivero A; Pellicano R; Cassader M; Gambino R; Bo S; Ciccone G; Rizzetto M; Saracco G
    Am J Gastroenterol; 2008 Oct; 103(10):2481-7. PubMed ID: 18702647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. INCREASE OF LIPIDS DURING HCV TREATMENT: VIRUS ACTION OR MEDICATION?
    Andrade VG; Yamashiro FDS; Oliveira CV; Kurozawa LL; Moreira A; Silva GF
    Arq Gastroenterol; 2018; 55(2):184-187. PubMed ID: 30043871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a.
    Hofer H; Bankl HC; Wrba F; Steindl-Munda P; Peck-Radosavljevic M; Osterreicher C; Mueller C; Gangl A; Ferenci P
    Am J Gastroenterol; 2002 Nov; 97(11):2880-5. PubMed ID: 12425563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to anti-HCV therapy in HIV-HCV-coinfected patients: does the lipid profile really have an effect?
    Petit JM; Carrat F; Duong M; Halfon P; Duvillard L; Bani-Sadr F; Chavanet P; Cacoub P; Piroth L
    Antivir Ther; 2010; 15(5):797-800. PubMed ID: 20710062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of pegylated interferon α-2b and ribavirin in chronic hepatitis C virus (genotypes 1 and 4) infection.
    Wiśniewska-Ligier M; Pawłowska M; Pilarczyk M; Halota W; Woźniakowska-Gęsicka T
    J Pediatr Gastroenterol Nutr; 2013 Dec; 57(6):694-9. PubMed ID: 23942001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of hypolipidemia in chronic hepatitis C patients after successful antiviral therapy.
    Kuo YH; Chuang TW; Hung CH; Chen CH; Wang JH; Hu TH; Lu SN; Lee CM
    J Formos Med Assoc; 2011 Jun; 110(6):363-71. PubMed ID: 21741004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2'-,5'-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C.
    Kim KI; Kim SR; Sasase N; Taniguchi M; Harada S; Kinoshita K; Kim SH; Akimoto Y; Shikata M; Kimura N; Izawa S; Ohtani A; Nakao K; Motojima M; Kinoshita M; Hirai M; Ohzu M; Hirooka T; Nabeshima S; Ishii F; Tanaka K; Hotta H
    J Clin Pharm Ther; 2006 Oct; 31(5):441-6. PubMed ID: 16958821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load.
    Arase Y; Suzuki F; Akuta N; Sezaki H; Suzuki Y; Kawamura Y; Kobayashi M; Hosaka T; Yatsuji H; Hirakawa M; Saito S; Ikeda K; Kobayashi M; Kumada H
    Intern Med; 2009; 48(5):253-8. PubMed ID: 19252344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.